Literature DB >> 10799053

Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products.

P Roberts1.   

Abstract

The inactivation of enveloped viruses by two different solvent/detergent combinations, i.e. tri-n-butyl phosphate (TNBP)/Triton X-100 or TNBP/Tween 80, has been investigated using a high purity factor VIII (Replenate) and factor IX (Replenine) respectively. Treatment with TNBP/Triton X-100 rapidly inactivated all the typical enveloped viruses tested, i.e. Sindbis, semliki forest virus (SFV), herpes simplex virus type-1 (HSV-1) and vesicular stomatitis virus (VSV), by 3.7-5.8 log within 15 seconds. While virus inactivation with TNBP/Tween 80 was slower, effective inactivation of Sindbis, HSV-1, VSV and human immunodeficiency virus type-1, i.e. 4.1-->6.3 log, occurred within 30 minutes. In contrast, vaccinia virus was relatively resistant to inactivation in either of these solvent/detergent combinations. Incubation times of 10 minutes for TNBP/Triton X-100 or 6-24 hours for TNBP/Tween 80, were required to reach inactivation levels of about 4 log.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799053     DOI: 10.1006/biol.1999.0236

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  7 in total

1.  Orthopox Viruses: Infections in Humans.

Authors:  Georg Pauli; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen; Carl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2010-11-17       Impact factor: 3.747

2.  Maturation of the Gag core decreases the stability of retroviral lipid membranes.

Authors:  Candice Davidoff; Riley J Payne; Sharon H Willis; Benjamin J Doranz; Joseph B Rucker
Journal:  Virology       Date:  2012-09-17       Impact factor: 3.616

3.  Inactivation and Removal of Chikungunya Virus and Mayaro Virus from Plasma-derived Medicinal Products.

Authors:  Constanze Yue; Sebastian Teitz; Tomoyuki Miyabashi; Klaus Boller; Lia Laura Lewis-Ximenez; Sally A Baylis; Johannes Blümel
Journal:  Viruses       Date:  2019-03-07       Impact factor: 5.048

4.  Antiviral activity of selected antimicrobial peptides against vaccinia virus.

Authors:  Ketha V K Mohan; Shilpakala Sainath Rao; Chintamani D Atreya
Journal:  Antiviral Res       Date:  2010-03-27       Impact factor: 5.970

Review 5.  Pathogen inactivation techniques.

Authors:  J P R Pelletier; S Transue; E L Snyder
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

6.  Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.

Authors:  Herbert O Dichtelmüller; Lothar Biesert; Fabrizio Fabbrizzi; Rodrigo Gajardo; Albrecht Gröner; Ilka von Hoegen; Juan I Jorquera; Christoph Kempf; Thomas R Kreil; Dominique Pifat; Wendy Osheroff; Gerhard Poelsler
Journal:  Transfusion       Date:  2009-05-20       Impact factor: 3.157

7.  Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products.

Authors:  K M Remington; S R Trejo; G Buczynski; H Li; W P Osheroff; J P Brown; H Renfrow; R Reynolds; D Y Pifat
Journal:  Vox Sang       Date:  2004-07       Impact factor: 2.144

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.